The Santis team shares its insights on the key sectors and factors driving decisions and change in the health care and life sciences sector across Canada.
INSIGHTS: UHN’s Award in Transplant Innovation Obscures Two Deeper Challenges: Organ Donation and Technology Commercialization
INSIGHTS: Wynne’s health-care Hail Mary
Patrick Nelson, Principal at Santis Health, wrote a guest column in the Toronto Sun on Premier Kathleen Wynne's recent health care commitments.
Read MoreNEWS: Former PC policy advisor Emily Beduz joins Santis Health as Consultant
Toronto, ON – April 6, 2018 – Santis Health is pleased to announce that former Progressive Conservative staffer Emily Beduz has joined the Santis team as a Consultant.
Read MoreSUMMARY: Premier Wynne shuffles cabinet (January 2018)
On January 17, 2018, Premier Kathleen Wynne shuffled cabinet to fill vacancies left by current ministers Brad Duguid, Liz Sandals and Deb Matthews who are not running for re-election in June.
Read MoreSUMMARY: Federal Cabinet Shuffle (2017)
Today, Prime Minister Justin Trudeau gave his year-old cabinet a new look. Sources say the shuffle comes as the Canadian government prepares for the priorities of a new administration in Washington.
Read MoreSUMMARY: Auditor General of Ontario's 2017 Annual Report
Santis highlights key findings related to health care from Bonnie Lysyk’s annual report, released in 2017. It covers value-for-money audits including cancer treatment services, community health centres, laboratory services, public drug programs and chronic disease prevention. Emergency management is also tabled.
Read MoreSUMMARY: Health care commitments from the newly-released Ontario PC platform
Leading up to the November 2018 election, “The People’s Guarantee” highlights five key commitments including the “largest mental health commitment in Canadian provincial history.”
Read MoreSUMMARY: Federal cabinet shuffle sees Petitpas Taylor replace Jane Philpott.
In August 2017, Prime Minister Justin Trudeau shuffled his cabinet and made significant changes that impact the Health portfolio.
Read MoreOPINION: Lower drug prices ahead, but at what cost?
Will the current drive for lower patented drug prices be the next thing to prove the old adage “if something is too good to be true, it probably is”? The answer is we won’t really know until we consider the possible trade-offs associated with policy initiatives using regulatory instruments to push prices lower.
Read More